Dyskinesia in Parkinson disease: back for the future?
Francois J G
FJ
Vingerhoets
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020820:Dyskinesias / Q000000981:diagnostic imaging / Q000209:etiology*; D006801:Humans; D010300:Parkinson Disease / Q000150:complications* / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D013569:Synapses / Q000187:drug effects*; D013747:Tetrabenazine / Q000031:analogs & derivatives
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D019275:Radiopharmaceuticals; C032811:dihydrotetrabenazine; D013747:Tetrabenazine